08.01.2022

Dr. Reddy's Laboratories Enters Into a Licensing Agreement to Obtain Rights for the Private Label Version of Lumify in the US

Dr. Reddy's Laboratories, along with its subsidiaries, announced it has entered into a licensing agreement with Princeton, New Jersey-based Slayback Pharma to acquire rights in Slayback's Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify in United States. Lumify (Bausch + Lomb) is an over-the-counter (OTC) eye drop that can be used to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr. Reddy's exclusive rights to the product outside the US.

Slayback Pharma is the first company to file an abbreviated new drug application for the private label equivalent for Lumify with the FDA under Paragraph IV certification. The abbreviated NDA is currently under FDA review and covers Brimonidine Tartrate Ophthalmic Solution 0.025% in 2.5 ml and 7.5 ml fill volumes.

"We are pleased to license this important OTC ophthalmic product for the U.S. market," Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's, said in a company news release. "This product complements Dr. Reddy's growing OTC product portfolio in the eye care category that includes the private label versions of Pataday Once Daily Relief and Pataday Twice Daily Relief."

More in Business

08.15.2022

Opthea Announces Financing Deals for OPT-302 in Wet AMD

Eyewire News

How to Diagnose and Treat Nocturnal Lagophthalmos

ack e Ga ch, OD, AAO, and es e O De , OD, AAO

Eyetube

08.08.2022

Clearside Biomedical Enters Into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for Up to $65 Million

Eyewire News

Next Article

07.29.2022

Lenstec Receives FDA Approval for the SBL-3 Multifocal IOL

Lenstec Announced that its SBL-3 IOL has been approved by the FDA. The SBL-3 IOL (Segmented Bifocal Lens) is a next generation asymmetric multifocal refractive IOL that provides patients with near, intermediate and distance vision. Its patented design allows for improved contrast sensitivity and minimized halo and glare (dysphotopsias) commonly associated with other traditional 'concentric ring' multifocal IOLs, according to a company news release.

The segmented optic design is the first of its kind in the US. Lenstec's patented four point fixation and design allow surgeons confidence in the IOLs effective lens position within the capsule. Its availability in 0.25 diopter power increments, along with tolerances (+/- 0.11 diopters from labeled power), assists surgeons in achieving the best refractive outcomes possible.

"SBL 3 lens patients reported high quality distance and near vision, without the headache of severe dysphotopsia issues, and we had no complaints with computer vision," James Loden, MD, a principal investigator in the FDA trial, said in the news release.

Sebastian Heersink, MD, another FDA trial principal investigator, stated, "In my own experience with the SBL-3, I have been very impressed with the quality and range of functional vision patients obtained, as well as their overall happiness. It performs well in low lighting and patients report excellent night driving. It's a great lens that I wouldn't hesitate to have implanted in my own eyes."

More in Cataract

08.16.2022

First SBL-3 ClearView Multifocal Intraocular Lens Implanted in US

Eyewire News

08.16.2022

Sight Sciences Announces Long Term Safety and Effectiveness Data of Standalone Use of the Omni Surgical System in Patients with Open Angle Glaucoma

Eyewire News

0 16 2022

First Patients Treated with Lensar's ALLY Adaptive Cataract Treatment System

Eyewire News